Esperion Therapeutis.Inc. buy WatchMen
Start price
14.10.23
/
40%
€0.82
Target price
14.10.24
€10.00
Performance (%)
137.85%
End price
15.10.24
€1.94
Summary
This prediction ended on 15.10.24 with a price of €1.94. With a performance of 137.85% the BUY prediction by WatchMen was a big success. WatchMen has 40% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -4.489% | -4.489% | 50.210% |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
Comments by WatchMen for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Buy Esperion Therapeutis.Inc.
Kursziel gesetzt auf 10,0
In the thread Trading Esperion Therapeutis.Inc.
Die von WatchMen gewählte maximale Laufzeit wurde überschritten
Stopped prediction by WatchMen for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€2.80
04.10.25
04.10.25
-
04.10.26
04.10.26
-20.80%
08.10.25
08.10.25
